drugset / Trial / NCT01742611

Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

NCT01742611

Phase 3 Completed 105 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease patients with hyperphosphatemia not on dialysis.

Timeline

Start
2013-03
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bixalomer Small molecule Oral